These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23058032)

  • 1. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
    Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
    Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S; Lumachi F; Stellini E; Favero L
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.
    Pakosch D; Papadimas D; Munding J; Kawa D; Kriwalsky MS
    Oral Maxillofac Surg; 2013 Dec; 17(4):303-6. PubMed ID: 23242941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the mandible associated with bevacizumab therapy.
    Santos-Silva AR; Belizário Rosa GA; Castro Júnior Gd; Dias RB; Prado Ribeiro AC; Brandão TB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Jun; 115(6):e32-6. PubMed ID: 23567260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
    Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
    J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
    Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
    Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit.
    Dişel U; Beşen AA; Özyılkan Ö; Er E; Canpolat T
    Oral Oncol; 2012 Feb; 48(2):e2-3. PubMed ID: 21865077
    [No Abstract]   [Full Text] [Related]  

  • 11. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws.
    Ramírez L; López-Pintor RM; Casañas E; Arriba Ld; Hernández G
    Oral Health Prev Dent; 2015; 13(5):385-93. PubMed ID: 25884045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab-related osteneocrosis of the jaw.
    Serra E; Paolantonio M; Spoto G; Mastrangelo F; Tetè S; Dolci M
    Int J Immunopathol Pharmacol; 2009; 22(4):1121-3. PubMed ID: 20074477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
    Antonuzzo L; Lunghi A; Petreni P; Brugia M; Laffi A; Giommoni E; Mela MM; Mazzoni F; Balestri V; Costanzo FD
    Curr Med Chem; 2017; 24(28):3068-3076. PubMed ID: 28494743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
    Fusco V; Santini D; Armento G; Tonini G; Campisi G
    Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer].
    Sato M; Ono F; Yamamura A; Onochi S
    Nihon Shokakibyo Gakkai Zasshi; 2013 Apr; 110(4):655-9. PubMed ID: 23558129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab, sunitinib: osteonecrosis of the jaw.
    Prescrire Int; 2011 Jun; 20(117):155. PubMed ID: 21682016
    [No Abstract]   [Full Text] [Related]  

  • 19. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
    O'Halloran M; Boyd NM; Smith A
    Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.